Reduced tetracycline bioavailability caused by magnesium aluminum silicate in liquid formulations of bismuth subsalicylate.

What Was Tested

The paper reports a study of Bismuth and Tetracycline, published as a randomized controlled trial.

In addition, standard in vitro ultraviolet spectrophotometric methods were used to determine the capacity for complexation of bismuth with tetracycline and for adsorption of tetracycline to Veegum.

Why It Was Studied

Bismuth subsalicylate, tetracycline hydrochloride, and metronidazole are widely used in combination for the treatment of Helicobacter pylori infections.

As a result, there is renewed interest in the interaction between tetracycline and bismuth subsalicylate.

Who Took Part

The age groups tagged for this paper are teenagers, adults and middle-aged adults, both men and women.

Eleven healthy volunteers participated in a randomized three-period, three-treatment complete crossover study with a 7-day washout interval between treatments.

How the Study Was Run

In design terms this was a randomized and crossover study.

Random assignment meant chance, not the researchers, decided who got Bismuth and who got the comparison, which limits bias.

In the crossover set-up each of the participants took both Bismuth and the comparison in turn, acting as their own control.

Serum was assayed for tetracycline concentration by HPLC.

What Was Measured

Topics PubMed links to this paper include Aluminum Compounds, Antacids, Biological Availability, Bismuth, Chromatography, High Pressure Liquid, Intestinal Absorption and Magnesium Compounds.

What This Means in Plain Language

The paper is a randomized and crossover study of Bismuth and Tetracycline.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1997 (The Annals of pharmacotherapy), a journal based in United States.

More context: all human trials.